Stock REVB REVELATION BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Market Closed - Nasdaq
Other stock markets
 21:00:00 16/05/2024 BST 		5-day change 1st Jan Change
1.87 USD -4.10% Intraday chart for Revelation Biosciences, Inc. -15.00% -87.55%
05-10 Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-22 Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday on Unchanged Fed Rate, Upcoming Earnings
MT
Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury
CI
Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
BU
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
BU
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
BU
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
BU
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
BU
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
CI
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
BU
Revelation Biosciences : Announces Pricing of Upcoming Automatic Unit Separation - Form 8-K
PU
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
BU
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REVB Stock
  4. News Revelation Biosciences, Inc.
  5. Highlights